Mesoblast FY2026 slides: $115M revenue marks commercial transition

Mesoblast Limited, a biotech company transitioning to commercial drug manufacturing, reported US$115 million in net revenue for the fiscal year ending June 30, 2026 - its first full year of RYONCIL sales. CEO Silviu Itescu highlighted the significant commercial progress, with the drug achieving an 84% survival rate in pediatric patients.

Despite solid revenue performance, shares fell slightly in regular trading due to continued losses and a 2.5% revenue miss. The company invested US$39.7 million in research and development, focusing on Phase 3 clinical trials and manufacturing capacity. Mesoblast secured new capital, including a US$125 million credit line, to support its growth.

The company also announced a registration trial for expanding RYONCIL's usage to adult patients with SR-aGvHD, and a Phase 3 trial for chronic low back pain, demonstrating strong market potential.